Assignee
EMENDOBIO INC
US·15 granted patents·40 pending applications·5 citations·filing 2017–2025
Top patents by PatentIndex Score
55 records- 0185US11666641B2CRISPR nucleaseEMENDOBIO INC·Filed 2020·Granted Jun 6, 2023·2 cites·39 claims
- 0284US11827879B2Differential knockout of an allele of a heterozygous bestrophin 1 geneEMENDOBIO INC·Filed 2018·Granted Nov 28, 2023·3 cites·11 claims
- 0376US2025057988A1Guide RNA That Targets A Mutant Human Guanylate Cyclase 2A AlleleEMENDOBIO INC·Filed 2024·Application pending·0 cites
- 0476US2026028626A1Differential Knockout of An Allele of A Heterozygous Elane Gene - IIEMENDOBIO INC·Filed 2025·Application pending·0 cites
- 0575US2026078415A1Differential Knockout of an Allele of a Heterozygous Elane GeneEMENDOBIO INC·Filed 2025·Application pending·0 cites
- 0674US2024229024A9Compositions for genome editingEMENDOBIO INC·Filed 2023·Application pending·0 cites
- 0773US2024132881A1Differential knockout of an allele of a heterozygous bestrophin 1 geneEMENDOBIO INC·Filed 2023·Application pending·0 cites
- 0872US2024384306A1Compositions And Methods For Promoting Gene Editing of CXCR4 GeneEMENDOBIO INC·Filed 2024·Application pending·0 cites
- 0970US2026055399A1Differential Knockout of An Allele of A Heterozygous Fibrinogen Alpha Chain (FGA) GeneEMENDOBIO INC·Filed 2025·Application pending·0 cites
- 1069US2025197822A1Novel omni-59, 61, 67, 76, 79, 80, 81 and 82 crispr nucleasesEMENDOBIO INC·Filed 2024·Application pending·0 cites
- 1168US2024226246A9Novel omni-50 crispr nucleaseEMENDOBIO INC·Filed 2023·Application pending·0 cites
- 1266US2026091113A1Biallelic Knockout of CTLA4EMENDOBIO INC·Filed 2023·Application pending·0 cites
- 1366US2026097123A1Biallelic Knockout of CIITAEMENDOBIO INC·Filed 2023·Application pending·0 cites
- 1466US2026097121A1Biallelic Knockout of CISHEMENDOBIO INC·Filed 2023·Application pending·0 cites
- 1566US2026085331A1Biallelic Knockout of PDCD1EMENDOBIO INC·Filed 2023·Application pending·0 cites
- 1665US12480140B2Differential knockout of an allele of a heterozygous ELANE geneEMENDOBIO INC·Filed 2019·Granted Nov 25, 2025·0 cites·12 claims
- 1764US12435334B2Differential knockout of an allele of a heterozygous ELANE gene-IIEMENDOBIO INC·Filed 2020·Granted Oct 7, 2025·0 cites·7 claims
- 1864US11946077B2OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleasesEMENDOBIO INC·Filed 2021·Granted Apr 2, 2024·0 cites·21 claims
- 1963US12359196B2Differential knockout of an allele of a heterozygous fibrinogen alpha chain (FGA) geneEMENDOBIO INC·Filed 2018·Granted Jul 15, 2025·0 cites·3 claims
- 2062US2026021141A1Strategies For Knock-Ins At APLP2 Safe Harbor SitesEMENDOBIO INC·Filed 2023·Application pending·0 cites
- 2161US12168062B2Guide RNA that targets a mutant human guanylate cyclase 2A alleleEMENDOBIO INC·Filed 2018·Granted Dec 17, 2024·0 cites·6 claims
- 2260US12258599B2Method to inactivate a mutant allele of an ELANE geneEMENDOBIO INC·Filed 2020·Granted Mar 25, 2025·0 cites·8 claims
- 2360US2025283115A1Engineered high fidelity omni-50 nuclease variantsEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 2460US2025043260A1Engineered High Activity Omni-79 Nuclease VariantsEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 2560US2024350665A1Hepatitis b virus (hbv) knockoutsEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 2660US2025277202A1Knockout of a mutant allele of an elane geneEMENDOBIO INC·Filed 2025·Application pending·0 cites
- 2759US11795453B2Compositions for genome editingEMENDOBIO INC·Filed 2017·Granted Oct 24, 2023·0 cites·19 claims
- 2859US2020123542A1Rna compositions for genome editingEMENDOBIO INC·Filed 2019·Application pending·0 cites
- 2958US12529043B2OMNI-103 CRISPR nucleaseEMENDOBIO INC·Filed 2024·Granted Jan 20, 2026·0 cites·11 claims
- 3057US2025017970A1Reduced Expression of Sarm1 For Use In Cell TherapyEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 3156US12031149B2Compositions and methods for promoting gene editing of CXCR4 geneEMENDOBIO INC·Filed 2020·Granted Jul 9, 2024·0 cites·12 claims
- 3256US2024175035A1Compositions and methods for treating hypercholesterolemiaEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 3355US12091688B2OMNI-103 CRISPR nucleaseEMENDOBIO INC·Filed 2022·Granted Sep 17, 2024·0 cites·24 claims
- 3455US2025034596A1Omni-103 CRISPR Nuclease-RNA ComplexesEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 3555US2025018056A1Strategies for knock-ins at c3 safe harbor sitesEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 3655US2024175013A1Biallelic knockout of tracEMENDOBIO INC·Filed 2021·Application pending·0 cites
- 3754US12274758B2Guide RNA that targets a mutant human inosine monophosphate deyhydrogenase I alleleEMENDOBIO INC·Filed 2018·Granted Apr 15, 2025·0 cites·6 claims
- 3852US2023383273A1Novel omni 56, 58, 65, 68, 71, 75, 78, and 84 crispr nucleasesEMENDOBIO INC·Filed 2021·Application pending·0 cites
- 3952US2025011741A1Omni 263, 264, 266, 268, 269, 271, 274, 275, 276, 278, 279, 280, 281, 283, 284, 286, 287, 288, 290, 291, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 375, 376,EMENDOBIO INC·Filed 2022·Application pending·0 cites
- 4051US2024000970A1Differential knockout of a heterozygous allele of lrrk2EMENDOBIO INC·Filed 2021·Application pending·0 cites
- 4151US2024376453A1Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleasesEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 4251US2019330620A1Rna compositions for genome editingEMENDOBIO INC·Filed 2017·Application pending·0 cites
- 4350US2022136013A1Differential knockout of a heterozygous allele of stat1EMENDOBIO INC·Filed 2020·Application pending·0 cites
- 4450US2023212562A1Differential knockout of a heterozygous allele of samd9lEMENDOBIO INC·Filed 2021·Application pending·0 cites
- 4549US12454705B2Differential knockout of an allele of a heterozygous apolipoprotein A1 (APO1A) geneEMENDOBIO INC·Filed 2019·Granted Oct 28, 2025·0 cites·14 claims
- 4649US2023287428A1Biallelic knockout of sarm1EMENDOBIO INC·Filed 2021·Application pending·0 cites
- 4749US2022213456A1Novel omni crispr nucleasesEMENDOBIO INC·Filed 2020·Application pending·0 cites
- 4849US2025011740A1Novel omni 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 crispr nucleasesEMENDOBIO INC·Filed 2022·Application pending·0 cites
- 4949US2022154157A1New engineered high fidelity cas9EMENDOBIO INC·Filed 2020·Application pending·0 cites
- 5048US11274288B2Compositions and methods for promoting homology directed repair mediated gene editingEMENDOBIO INC·Filed 2017·Granted Mar 15, 2022·0 cites·20 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →